Erin Fox has tracked drug shortages for more than 20 years, and she sees no easy solutions for what has become a record run.
Total active shortages hit an all-time high of 323 in this year鈥檚 first quarter, according to the University of Utah Drug Information Service. That鈥檚 up about 86% from a 10-year low of 174 last reached in 2017.
There were 48 new shortages recorded this year through March, according to the data, published by the American Society of Health-System Pharmacists.
Still, Fox also sees positive news developing. The associate chief pharmacy officer at University of Utah Health spoke recently with The Associated Press. The conversation has been edited for clarity and length.
Q: Are there any signs that this is letting up?
A: Unfortunately, no. We haven鈥檛 necessarily solved some of the root causes.
We have, overall, relatively few manufacturers. (The U.S. Food and Drug Administration) halted inspections during COVID. Now they鈥檙e back, at factories that maybe haven鈥檛 been inspected for five or six years. They鈥檙e finding some things to fix. Those fixes can take anywhere from 6 to 18 months for production to get fully back on schedule.
Meanwhile, other companies don鈥檛 necessarily have the capacity to ramp up production to make up the difference.
It鈥檚 not the FDA鈥檚 fault. We want them to find those quality deficits. But when FDA goes out looking all at once, it can be pretty disruptive.
Q: What are the typical drugs that land on the shortage list?
A: Generic, injectable hospital drugs or older drugs. They are usually pretty low cost. There鈥檚 not a lot of resilience in the supply chain for another company to make up the difference.
We saw all those chemotherapy shortages last year in part because a large factory in India, (the FDA) found quality problems there. They made a large amount of the U.S. supply. The other companies were unable to quickly make up the difference.
Things have definitely improved, but that factory is still not running.
Q: What is one thing about shortages that patients underestimate?
A: They shouldn鈥檛 automatically assume they won鈥檛 be able to get that treatment.
It might be delayed or they might have to take a capsule instead of a pill. They might have to call their insurance company to ask if they will cover the brand because sometimes (that) is available while the generic is not.
Don鈥檛 panic. It鈥檚 frustrating to have to do a little bit of work, but usually you will still be able to get a treatment.
Q: Is there any good news?
A: Last year, Congress held four hearings on shortages. They鈥檙e still very interested. People are really starting to talk about doing hard work both on the policy side but also maybe a little bit of Congressional action to really try to move this problem forward.
I鈥檝e been leading our efforts to provide data on drug shortages since 2001. This is truly the most interest I鈥檝e ever seen.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute鈥檚 Science and Educational Media Group. The AP is solely responsible for all content.
